Research Article
Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps
Table 3
Model parameters for treatments.
| Parameter | Dementia | Predementia | Data source | Usual care | Florbetaben | Usual care | Florbetaben |
| % of patients receiving dementia medication at diagnosis | N/A | N/A | 28% | N/A | VA VISN 1 and user specification | If Dx = AD+ | 77% | 100% | N/A | 100% | | If Dx = non-AD | 67% | 0% | N/A | 0% | | Distribution of dementia medication | Dx = AD+ | Dx = Non-AD | | | VA VISN 1 | Donepezil | 63% | 66% | 76% | | Galantamine | 25% | 9% | 6% | | Rivastigmine | 5% | 4% | 1% | | Memantine | 7% | 21% | 17% | | Maximum dementia treatment duration allowed, years | Life time | 5 | User specification | Stopping dementia medication if MMSE score is below 10 | Yes | N/A | User specification |
|
|
AD: Alzheimer’s disease; Dx: dementia diagnosis; MMSE: mini-mental state examination; N/A: not applicable.
|